| Ytd | 42.11% | |
| 1y | 90.14% |
| Open | 4.01 | Prev Close | 4.02 | Low | 4.00 | High | 4.08 | Mkt Cap | 164.52M |
| Vol | 50.69K | Avg Vol | 300.78K | EPS | 1.93 | P/E | 2.08 | Forward P/E | -29.75 |
| Beta | 1.21 | Short Ratio | 2.60 | Inst. Own | 17.52% | Dividend | 0.25 | Div Yield | 6.20 |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 4.15 | 200-d Avg | 3.38 | 1yr Est | 3.25 |
ORMP News
Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday'
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan
Significant Appreciation in Alpha Tau (NASDAQ: DRTS) Position (up ~$128 Million) Scilex (NASDAQ: SCL
NEW YORK, June 17, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www
Oramed Pharmaceuticals is downgraded from 'Strong Buy' to 'Hold' due to the failed phase 3 trial for
Akanda (NASDAQ: AKAN - Get Free Report) and Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report)
Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innova
Lifeward Ltd. (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innov
Position s Lifeward as a diversified biomedical innovation company with clear path to profitability
Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report) and GN Store Nord (OTCMKTS:GNNDY - Get Free
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP - Get Free Report)'s stock price passed above its 50-day m
QuidelOrtho (NASDAQ: QDEL - Get Free Report) and Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Rep
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP - Get Free Report)'s stock price crossed above its 50-day
Positions Lifeward as a MedTech platform with a clear path to cashflow positive and long-term Biotec
Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Pos
Payment Closes Out Option Agreement Obligations; Oramed Retains $39 Million Outstanding debt, Conver
Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report) and GE HealthCare Technologies (NASDAQ: GEHC
Oramed remains viable after its flagship product failed FDA trials three years ago. Management ident
Strong Nine-Month Performance Driven by Strategic Investment Portfolio; Total Assets Increase 42% to
NEW YORK , Nov. 17, 2025 /PRNewswire/ -- The Board of Directors of Oramed Pharmaceuticals Inc. (the
Oramed Advancing Oral Insulin Program Independently; Announces Launch of New U.S. Trial Diversified
Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer
JERUSALEM, April 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”)
On Wednesday, 807 companies reached new 52-week lows.
On Friday, 1043 companies hit new 52-week lows.
On Monday, 721 companies achieved new lows for the year.
On Friday, 431 companies hit new 52-week lows.
During Wednesday's morning trading, 251 companies set new 52-week highs.
Stocks Which Set New 52-Week Low Yesterday, October 10th